ARTICLE | Clinical News
Cytovaxine: Phase I
October 7, 2002 7:00 AM UTC
Cytovax Biotechnologies Inc. (TSE:CBX), Edmonton, Alberta Product: Cytovaxine Business: Infectious diseases Therapeutic category: Vaccine Target: Immune cells Description: Peptide vaccine derived from...